What is Wedbush’s Estimate for PepGen FY2028 Earnings?

PepGen, Inc. (NASDAQ:PEPG) – Wedbush dropped their FY2028 earnings estimates for shares of PepGen in a report released on Thursday, September 25th. Wedbush analyst L. Chico now expects that the company will post earnings of ($1.34) per share for the year, down from their previous estimate of ($1.08). Wedbush currently has a “Outperform” rating and a $9.00 price target on the stock. The consensus estimate for PepGen’s current full-year earnings is ($2.73) per share.

A number of other analysts also recently issued reports on the stock. Guggenheim reissued a “buy” rating and issued a $6.00 price objective on shares of PepGen in a report on Wednesday, September 24th. HC Wainwright boosted their price objective on shares of PepGen from $8.00 to $12.00 and gave the company a “buy” rating in a report on Thursday. Finally, Stifel Nicolaus boosted their price objective on shares of PepGen from $9.00 to $12.00 and gave the company a “buy” rating in a report on Thursday. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, PepGen has an average rating of “Moderate Buy” and an average price target of $8.40.

PepGen Stock Performance

Shares of PEPG stock opened at $5.07 on Monday. The company has a market capitalization of $166.30 million, a price-to-earnings ratio of -1.71 and a beta of 1.18. The company has a 50-day simple moving average of $1.58 and a 200 day simple moving average of $1.48. PepGen has a 52 week low of $0.88 and a 52 week high of $9.94.

PepGen (NASDAQ:PEPG) last announced its earnings results on Thursday, August 7th. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.15.

Institutional Trading of PepGen

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Adage Capital Partners GP L.L.C. lifted its holdings in shares of PepGen by 68.8% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 1,350,000 shares of the company’s stock worth $1,897,000 after acquiring an additional 550,000 shares during the period. Woodline Partners LP bought a new stake in shares of PepGen during the 1st quarter worth approximately $1,097,000. Millennium Management LLC lifted its holdings in shares of PepGen by 1,033.2% during the 4th quarter. Millennium Management LLC now owns 156,636 shares of the company’s stock worth $594,000 after acquiring an additional 142,814 shares during the period. RBF Capital LLC bought a new stake in shares of PepGen during the 2nd quarter worth approximately $111,000. Finally, Nuveen LLC bought a new stake in shares of PepGen during the 1st quarter worth approximately $139,000. Institutional investors own 58.01% of the company’s stock.

About PepGen

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.